Allen Capital Group’s Jupiter Neurosciences JUNS Stock Holding History

Allen Capital Group’s Portfolio JUNS Stock Details JUNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$30.6K	–	298
2025 Q4	$30.6K	Buy	+400	New	+$39.9K	﹤0.01%	274

Other funds holding JUNS

Vestor Capital Chicago, Illinois $1.59B AUM 51.04% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MidFirst Bank Oklahoma City, Oklahoma $1.41B AUM

Allen Capital Group's JUNS Position: Q1 2026 in Review

Allen Capital Group sold out of Jupiter Neurosciences (JUNS) in Q1 2026, closing a stake of 400 shares — an estimated $30.6K sold.

Allen Capital Group first reported a position in JUNS in Q4 2025 and held it in 1 quarter. The position peaked at $30.6K in Q4 2025. 10 funds tracked by Wall St. Rank hold JUNS as of Q1 2026.

Allen Capital Group reported no remaining Jupiter Neurosciences position as of Q1 2026 after selling out during the quarter.
Allen Capital Group sold 400 Jupiter Neurosciences shares in Q1 2026, an estimated $30.6K.
Allen Capital Group first reported a position in Jupiter Neurosciences in Q4 2025 and held it in 1 quarter.
Allen Capital Group's Jupiter Neurosciences position peaked at $30.6K in Q4 2025.
10 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q1 2026.

Based on Allen Capital Group's 13F filing for Q1 2026, filed 27 May 2026.